There are 2949 resources available
214P - Impact of chemotherapy and hormonotherapy on acute skin toxicity of hypofractionated breast cancer radiotherapy
Presenter: Raouia Ben Amor
Session: E-Poster Display
Resources:
Abstract
215P - Identifying the best Ki67 cut-off for determining luminal breast cancer subtypes using immunohistochemical analysis and PAM50 genomic classification
Presenter: Roberto Escala Cornejo
Session: E-Poster Display
Resources:
Abstract
216P - The impact of pregnancy-associated breast cancer (PABC) according to immunohistochemical (IHC) subtype: A matched case-control study
Presenter: Wendy Muñoz-Montaño
Session: E-Poster Display
Resources:
Abstract
217P - Heterogeneity of PD-L1 expression at the protein and mRNA levels in early breast cancer
Presenter: Ioannis Zerdes
Session: E-Poster Display
Resources:
Abstract
218P - Comparison of gene mutations between Chinese male and female breast cancer patients through next-generation sequencing
Presenter: Zhuangqing Yang
Session: E-Poster Display
Resources:
Abstract
219P - Relationship among PDL1, androgen receptor (AR) and tumour infiltrating lymphocytes (TILs) in early triple negative breast cancer
Presenter: Luis Felipe Sánchez-Cousido
Session: E-Poster Display
Resources:
Abstract
220P - Annotating MammaPrint and BluePrint gene profile to the Hallmarks of cancer and understanding the biology of MammaPrint extreme risk groups
Presenter: Josien Haan
Session: E-Poster Display
Resources:
Abstract
221P - Long-term outcomes of patients with node-negative, ≤3cm, HER2+ breast cancer (BC) enrolled in ALTTO
Presenter: Daniel Eiger
Session: E-Poster Display
Resources:
Abstract
222P - Rates of cardiac adverse events in older versus younger adults receiving trastuzumab for HER2-positive early breast cancer: Results from 931 patients treated at The Royal Marsden
Presenter: Nicolò Matteo Luca Battisti
Session: E-Poster Display
Resources:
Abstract
223P - Safety and tolerability of subcutaneous trastuzumab (H SC) self-administered at home via single-use injection device (SID) in patients (pts) with HER2-positive early breast cancer (EBC): Primary and final analysis of the open-label, phase IIIB HOMERUS study
Presenter: Albert ten Tije
Session: E-Poster Display
Resources:
Abstract